EUVIMEDEUVIMED entdecken
Crossref

Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity

Jintao Hu, Julia Y Tsang, Jianlan Liu, Hong Hu, Dajiang Guo, Gary M Tse

Modern Pathology · 2026-03 · 39 (3) · 100935

DOI: 10.1016/j.modpat.2025.100935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-03. Verfasst von Jintao Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University …. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2) gene amplification and heterogeneity influence anti-HER2 therapy efficacy, but quantitative assessment of HER2 expression heterogeneity remains scarce. This study evaluates HER2 protein heterogeneity and its effect on neoadjuvant therapy (NAT) outcomes in HER2-positive breast cancer. In total, 295 patients with HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy were included. HER2 expression was quantified by the percentage of HER2-stained cells across intensities, and heterogeneity was assessed using quadratic entropy. The overall pathological complete response (pCR) rate was 51.86%. Patients with HER2 heterogeneity showed a 24.5% pCR rate, significantly

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyBiomarkers, TumorHumansFemaleMiddle AgedAdultPathologic Complete ResponseAgedTreatment Effect HeterogeneityTrastuzumabTreatment Outcome

Stichwörter der Autor:innen

HER2 heterogeneityHER2-HQEanti-HER2-targeted therapybreast cancerneoadjuvant therapyresidual tumor burden

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, TumorTrastuzumab

Autor:innen und Institutionen

  • Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Department of Pathology, Shenzhen People's Ho…
  • Department of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Precision Breast PATHology Lab, Li Ka Shing I…
  • Department of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
  • Department of Surgery, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.

Förderung

  • Wu Jieping Medical Foundation

Zitieren

APA

Hu, J., Tsang, J. Y., Liu, J., Hu, H., Guo, D., & Tse, G. M. (2026). Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity. Modern Pathology, 39(3), 100935. https://doi.org/10.1016/j.modpat.2025.100935

Vancouver

Hu J, Tsang JY, Liu J, Hu H, Guo D, Tse GM. Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity. Modern Pathology. 2026;39(3):100935. doi:10.1016/j.modpat.2025.100935

BibTeX
@article{Hu2026,
  author = {Hu, Jintao and Tsang, Julia Y and Liu, Jianlan and Hu, Hong and Guo, Dajiang and Tse, Gary M},
  title = {Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {3},
  pages = {100935},
  doi = {10.1016/j.modpat.2025.100935}
}
Kostenlos starten →